PE20120315A1 - Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipino - Google Patents

Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipino

Info

Publication number
PE20120315A1
PE20120315A1 PE2011001882A PE2011001882A PE20120315A1 PE 20120315 A1 PE20120315 A1 PE 20120315A1 PE 2011001882 A PE2011001882 A PE 2011001882A PE 2011001882 A PE2011001882 A PE 2011001882A PE 20120315 A1 PE20120315 A1 PE 20120315A1
Authority
PE
Peru
Prior art keywords
esprotonous
benzimidazole
biphenyl
methyl
candesartan
Prior art date
Application number
PE2011001882A
Other languages
English (en)
Inventor
Wataru Hoshina
Makoto Fukuta
Shigeyuki Marunaka
Original Assignee
Takeda Pharmaceutical
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43032637&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PE20120315(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Pharmaceutical filed Critical Takeda Pharmaceutical
Publication of PE20120315A1 publication Critical patent/PE20120315A1/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2013—Organic compounds, e.g. phospholipids, fats
    • A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4422—1,4-Dihydropyridines, e.g. nifedipine, nicardipine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2077—Tablets comprising drug-containing microparticles in a substantial amount of supporting matrix; Multiparticulate tablets
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
    • A61K9/2086—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat
    • A61K9/209—Layered tablets, e.g. bilayer tablets; Tablets of the type inert core-active coat containing drug in at least two layers or in the core and in at least one outer layer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
    • A61K9/2806—Coating materials
    • A61K9/2833—Organic macromolecular compounds
    • A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
    • A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Abstract

SE REFIERE A UNA COMPOSICION FARMACEUTICA SOLIDA QUE COMPRENDE: A) UN COMPUESTO BENZIMIDAZOL DE FORMULA (I) DONDE R1 ES UN GRUPO HETEROCICLICO QUE CONTIENE NITROGENO MONOCICLICO Y UN ATOMO DE HIDROGENO DESPROTONABLE, R2 ES CARBOXILO OPCIONALMENTE ESTERIFICADO, Y R3 ES ALQUILO INFERIOR OPCIONALMENTE SUSTITUIDO; SIENDO COMPUESTOS PREFERIDOS: 1-(CICLOHEXILOXICARBONILOXI)ETIL 2-ETOXI-1-[[2'-(1H-TETRAZOL-5-IL)BIFENIL-4-IL]METIL]BENZIMIDAZOL-7-CARBOXILATO, 2-ETOXI-1-[[2'-(1H-TETRAZOL-5-IL)BIFENIL-4-IL]METIL]-1H-BENZIMIDAZOL-7-CARBOXILICO, ACIDO 2-ETOXI-1-[[2'-(4,5-DIHIDRO-5-OXO-1,2,4-OXADIAZOL-3-IL)BIFENIL-4-IL]METIL]-1H-BENZIMIDAZOL-7-CARBOXILICO; B) UN ALCOHOL DE AZUCAR TAL COMO MANITOL, SORBITOL O ERITRITOL; C) UN ANTAGONISTA DE CALCIO TAL COMO AMLODIPINA, AZELNIDIPINA, ARANIDIPINA, ENTRE OTROS; Y D) POLIETILENO GLICOL DE PESO MOLECULAR DE 1.000 A 10.000. DICHA COMPOSICION PRESENTA UNA MEJOR ESTABILIDAD DEL DERIVADO BENZIMIDAZOL SIENDO UTIL EN EL TRATAMIENTO DE LA HIPERTENSION
PE2011001882A 2009-04-30 2010-04-28 Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipino PE20120315A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP2009111381 2009-04-30
JP2010068625 2010-03-24

Publications (1)

Publication Number Publication Date
PE20120315A1 true PE20120315A1 (es) 2012-04-07

Family

ID=43032637

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2011001882A PE20120315A1 (es) 2009-04-30 2010-04-28 Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipino

Country Status (24)

Country Link
EP (1) EP2424501A2 (es)
JP (1) JP5666471B2 (es)
KR (1) KR101797776B1 (es)
CN (1) CN102481248B (es)
AU (1) AU2010242308A1 (es)
BR (1) BRPI1014388A2 (es)
CA (1) CA2760073A1 (es)
CL (1) CL2011002662A1 (es)
CO (1) CO6470841A2 (es)
CR (1) CR20110581A (es)
DO (1) DOP2011000329A (es)
EA (1) EA201171329A1 (es)
EC (1) ECSP11011494A (es)
GE (1) GEP20135940B (es)
IL (1) IL215962A0 (es)
MA (1) MA33280B1 (es)
MX (1) MX2011011011A (es)
MY (1) MY158158A (es)
NZ (1) NZ596395A (es)
PE (1) PE20120315A1 (es)
SG (1) SG175794A1 (es)
TW (1) TWI438201B (es)
WO (1) WO2010126168A2 (es)
ZA (1) ZA201108375B (es)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PL236001B1 (pl) 2012-12-21 2020-11-30 Adamed Spolka Z Ograniczona Odpowiedzialnoscia Złożona kompozycja farmaceutyczna zawierająca kandesartan cyleksetylu oraz amlodypinę, sposób jej wytwarzania oraz jednostkowa postać dawkowania zawierająca tę kompozycję
KR101535586B1 (ko) * 2014-08-01 2015-07-09 에스케이케미칼주식회사 무정형 또는 열역학적 준 안정형 리바록사반을 포함하는 약학 제제
KR101806004B1 (ko) * 2015-01-30 2017-12-08 씨제이헬스케어 주식회사 칸데사르탄 및 암로디핀을 포함하는 약제학적 조성물
CN106668016B (zh) * 2015-11-11 2020-06-23 江苏先声药业有限公司 阿齐沙坦和苯磺酸氨氯地平组合物的固体制剂及其制备方法
JP2017210435A (ja) * 2016-05-25 2017-11-30 ダイト株式会社 イルベサルタン及びアムロジピンベシル酸塩配合錠の製造方法
JP2019001782A (ja) * 2017-06-14 2019-01-10 東和薬品株式会社 二層錠
JP7101464B2 (ja) * 2017-09-28 2022-07-15 エルメッド株式会社 アジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤の品質向上方法、並びにアジルサルタン又はその塩及びアムロジピン又はその塩含有錠剤及びその製造方法
CN108210472A (zh) * 2017-12-15 2018-06-29 蚌埠丰原医药科技发展有限公司 一种西尼地平固体分散体片剂及其制备方法
CN108685925B (zh) * 2018-05-15 2019-12-06 徐州医科大学 一种化合物AB-38b在制备治疗糖尿病肾病药物方面的应用
JP2020075869A (ja) * 2018-11-05 2020-05-21 日本ケミファ株式会社 カルシウム拮抗剤及びアンジオテンシンｉｉ受容体拮抗剤を有効成分として含有する錠剤
JP7206872B2 (ja) * 2018-12-07 2023-01-18 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
JP2020090471A (ja) * 2018-12-07 2020-06-11 ニプロ株式会社 アジルサルタン及びアムロジピンを含有する医薬組成物及びその製造方法
JP7441105B2 (ja) 2020-03-31 2024-02-29 日本ジェネリック株式会社 アジルサルタン及びアムロジピンベシル酸塩を含有するフィルムコーティング錠

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2814513B2 (ja) * 1988-02-03 1998-10-22 吉富製薬株式会社 溶出性の改良された製剤組成物
CA2125251C (en) * 1993-06-07 2005-04-26 Yoshiyuki Inada A pharmaceutical composition for angiotensin ii-mediated diseases
JP3057471B2 (ja) * 1993-06-07 2000-06-26 武田薬品工業株式会社 アンジオテンシンｉｉ介在性諸疾患の予防または治療剤
WO2002006234A1 (fr) 2000-07-17 2002-01-24 Takeda Chemical Industries, Ltd. Derives de sulfonate, procede de production et utilisation de ces derives
EP1369130A1 (en) * 2001-03-16 2003-12-10 Takeda Chemical Industries, Ltd. Process for producing sustained release preparation
US20050032854A1 (en) * 2001-12-03 2005-02-10 Kiminori Kawahara Insulin resistance improving agents
JP4743684B2 (ja) * 2002-05-22 2011-08-10 塩野義製薬株式会社 難水溶性薬物の溶出性を改善する方法
US20070004736A1 (en) 2002-11-22 2007-01-04 Keiji Kubo Imidazole derivative, process for producing the same, and use
WO2005030740A1 (ja) 2003-09-30 2005-04-07 Takeda Pharmaceutical Company Limited チアゾリン誘導体およびその用途
US7820673B2 (en) 2003-12-17 2010-10-26 Takeda Pharmaceutical Company Limited Urea derivative, process for producing the same, and use
TWI396686B (zh) 2004-05-21 2013-05-21 Takeda Pharmaceutical 環狀醯胺衍生物、以及其製品和用法
JP2006321726A (ja) * 2005-05-17 2006-11-30 Sysmex Corp 錠剤の溶出性調整方法
BRPI0612674B8 (pt) * 2005-06-27 2021-05-25 Daiichi Sankyo Co Ltd preparação farmacêutica, uso de um antagonista do receptor de angiotensina ii e um bloqueador do canal de cálcio
TWI407978B (zh) * 2005-06-27 2013-09-11 Sankyo Co 濕粒狀藥物之製備方法
DE102005031577A1 (de) * 2005-07-06 2007-01-11 Bayer Healthcare Ag Pharmazeutische Darreichungsformen enthaltend eine Wirkstoffkombination von Nifedipin und/oder Nisoldipin und einem Angiotensin-II Antagonisten
CN101652139A (zh) * 2007-03-29 2010-02-17 第一三共株式会社 药物组合物
UY32126A (es) * 2008-09-25 2010-04-30 Takeda Pharmaceutical Composición farmacéutica sólida

Also Published As

Publication number Publication date
MY158158A (en) 2016-09-15
JP5666471B2 (ja) 2015-02-12
CL2011002662A1 (es) 2012-06-15
DOP2011000329A (es) 2011-11-15
CA2760073A1 (en) 2010-11-04
WO2010126168A2 (en) 2010-11-04
MX2011011011A (es) 2011-11-02
AU2010242308A1 (en) 2011-12-01
CN102481248B (zh) 2013-12-11
BRPI1014388A2 (pt) 2016-04-05
JP2012525323A (ja) 2012-10-22
TW201041873A (en) 2010-12-01
CO6470841A2 (es) 2012-06-29
SG175794A1 (en) 2011-12-29
IL215962A0 (en) 2012-01-31
KR20120026060A (ko) 2012-03-16
GEP20135940B (en) 2013-10-10
WO2010126168A3 (en) 2011-03-03
KR101797776B1 (ko) 2017-11-14
MA33280B1 (fr) 2012-05-02
ZA201108375B (en) 2013-01-30
ECSP11011494A (es) 2011-12-30
NZ596395A (en) 2013-06-28
EA201171329A1 (ru) 2012-05-30
CR20110581A (es) 2012-01-19
CN102481248A (zh) 2012-05-30
TWI438201B (zh) 2014-05-21
EP2424501A2 (en) 2012-03-07

Similar Documents

Publication Publication Date Title
PE20120315A1 (es) Una composicion farmaceutica que comprende candesartan, candesartan cilexetil, o azilsartan, combinado con amlodipino
PE20120018A1 (es) Composicion farmaceutica de linagliptina y 1-cloro-4-(b-d-glucopiranos-1-il)-2-[4-((s)-tetrahidrofuran-3-iloxi)-bencil]-benceno, forma farmaceutica y procedimiento para su preparacion
NZ594597A (en) Substituted piperidines as ccr3 antagonists
PE20120509A1 (es) Derivados 9,9 difluoro-9h-fluoreno que tiene actividad antiviral
AR067390A1 (es) Imidazoles trisustituidos, un proceso para su elaboracion, composiciones farmaceuticas que los comprenden y su uso en la preparacion de medicamentos para el tratamiento de enfermedades mediadas por el antagonismo de los receptores ccr
PE20142448A1 (es) Compuestos de n-alquiltriazol como antagonistas de lpar
CL2011000625A1 (es) Preparación sólida que comprende 2-etoxi-1-((2'-(5-oxo-4,5-dihidro-1,2,4-oxadiazol-3-il)bifenil-4-il)metil)-1h-bencimidazol-7-carboxilato de (5-metil-2-oxo-1,3-dioxol-4-il)metilo, un agente regulador de ph y un compuesto antagonista de calcio; y metodos para utilizar y mejorar disolucion del compuesto en la preparacion solida.
CL2009000394A1 (es) Compuestos derivados de n-(1h-indazol-5-il)pirrolidin-3-carboxamida sustituida, inhibidores de erk; composicion farmaceutica; y su uso en el tratamiento del cancer.
ATE483707T1 (de) 2-cyclopropylthiazolderivate
PE20080252A1 (es) Uso de bifenilamidas de acido arilcarboxilico para el tratamiento de semillas
AR065850A1 (es) Composicion farmaceutica solida que comprende un derivado de benzimidazol-7-carboxilato y un agente de control de ph
UY31863A (es) Combinaciones de drogas que comprenden un inhibidor de dgat y un agonista de ppar
PE20080927A1 (es) Derivados de benzoil-amino-heterociclilo como activadores de la glucoquinasa (glk)
PE20142301A1 (es) Uracilos sustituidos biciclicamente y uso de los mismos
PE20081315A1 (es) Derivados de benzimidazol como antagonistas de vr-1
CO6761298A2 (es) Combinaciones que comprenden antipsicóticos atípocos y antagonistas taar1
AR055009A1 (es) Compuesto profarmaco de amida de gemcitabina, composicion farmaceutica que lo comprende y su uso para la manufactura de un medicamento
CL2011003371A1 (es) Composicion farmaceutica de dosis fija, oral, solida y estable que comprende irbesartan, besilato de amlodipino y excipientes; procedimientos de preparacion; uso en el tratamiento de la hipertension.
PE20091032A1 (es) Composicion que contiene n-(3-metoxi-5-metilpirazin-2-il)-2-(4-[1,3,4-oxadiazol-2-il]fenil)piridin-3-sulfonamida (zibotentan)
AR076300A1 (es) Derivados de pirimidin imidazoles sustituidos, inhibidores de gsk3, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento del alzheimer, enfermedades neurodegenerativas agudas, diabetes y otras enfermedades.
PE20090654A1 (es) Formulaciones galenicas que contienen alisquireno y valsartan
AR065714A1 (es) Sal clorhidrato de 5- (3-( 3- hidroxifenoxi ) azetidin- 1 - il ) - 5 - metil - 2, 2 - difenilhexanamida
PL2021002T3 (pl) Kompozycja farmaceutyczna zawierająca medoksomil olmesartanu
CO6321246A2 (es) Compuestos novedosos activos como antagonistas de receptor muscarinico
PE20091718A1 (es) (pirazolilcarbonil) imidazolidinonas sustituidas con actividad antiviral

Legal Events

Date Code Title Description
FC Refusal